Related Experiment Video

Updated: Jul 14, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Trastuzumab (herceptin) for early-stage breast cancer

Gustavo Ismael1, Daniela Dornelles Rosa, Evandro de Azambuja

  • 1Medical Oncology Clinic, Jules Bordet Institute, l'Université Libre de Bruxelles, Boulevard de Waterloo, 125, 1000 Brussels, Belgium.

Hematology/Oncology Clinics of North America
|May 22, 2007
PubMed

Insights

Trastuzumab significantly improves outcomes for early breast cancer patients with HER2 amplification. This antibody therapy offers a crucial benefit in treating HER2-positive early-stage disease.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • HER2 gene amplification and protein overexpression are linked to aggressive breast cancer and poor survival.
  • Trastuzumab, a HER2-targeted monoclonal antibody, has proven effective in HER2-positive metastatic breast cancer.
  • Recent adjuvant trials provide new insights into trastuzumab's role in early-stage disease.

Purpose of the Study:

  • To summarize the key findings from five major adjuvant trials of trastuzumab in early breast cancer.
  • To analyze the differences and commonalities among these trials.
  • To highlight the established role of trastuzumab in HER2-positive early breast cancer treatment.

Main Methods:

  • Meta-analysis of five large-scale adjuvant clinical trials.
  • Inclusion of over 13,000 women diagnosed with early breast cancer.
  • Focus on patients with HER2-overexpressing or amplified tumors.

Main Results:

  • Trastuzumab demonstrated a significant benefit in the adjuvant treatment of HER2-positive early breast cancer.
  • Consistent efficacy across different trial designs and patient populations was observed.
  • The trials confirmed the critical role of HER2 status in treatment selection.

Conclusions:

  • Trastuzumab is a vital component in the adjuvant treatment of early breast cancer patients with HER2 amplification.
  • The findings support the routine use of trastuzumab in this patient group.
  • Further research may explore optimizing treatment duration and combinations.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...